人体血清白蛋白上多个动态合的结合点调节雌激醇的非线性结合.
Mohammad Anees1, Mark K Fugate1, Shalender Bhasin1
1Research Program in Men's Health, Aging, and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Endocrinology
|March 12, 2026
概括
雌二醇是雌二醇的一种.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 雌激醇主要与循环中的蛋白质结合,人血清白蛋白 (HSA) 是主要的载体.
- 传统观点认为,低亲和度,单位结合,但分子细节仍然不清楚.
研究的目的:
- 描述雌醇-HSA结合的分子相互作用和动力学.
- 通过HSA研究雌激醇运输的结构和能量基础.
主要方法:
- 使用平衡透析,光谱和表面等离子体共振 (SPR).
- 采用分子对接和结构网络分析来进行模型结合.
- 研究了不同度的雌激醇-HSA相互作用.
主要成果:
- 结合是非线性和不对称的,与固定的解离常数 (Kd) 不一致.
- SPR揭示了复杂的关联/解离动力学,具有多个阶段.
- 在HSA中确定了一个高亲和位点和额外的中等亲和位点,表明了全结合.
结论:
- 雌激醇-HSA结合是一个动态的多平衡过程,由结构变化驱动.
- 通过一种全结合机制,HSA积极调节雌激醇的生物可用性.
- 对于雌激醇-HSA相互作用的1:1静脉测量和固定Kd的正规模型不支持.
相关概念视频
Drug Distribution: Plasma Protein Binding
11.0K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
11.0K
The Equilibrium Binding Constant and Binding Strength
15.5K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.5K
The Equilibrium Binding Constant and Binding Strength
10.8K
10.8K
Drug Binding to Blood Components
615
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
615
Cooperative Allosteric Transitions
9.3K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.3K
Factors Affecting Protein-Drug Binding: Protein-Related Factors
637
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
637


